Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hypomethylating Agent”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05841771
What this trial is testing

Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.

Who this might be right for
Hypomethylating AgentVenetoclaxMyeloid Malignancy
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 78
Early research (Phase 1)Looking for participantsNCT06502145
What this trial is testing

Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndromes
Medical College of Wisconsin 12
Testing effectiveness (Phase 2)Study completedNCT01812252
What this trial is testing

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant

Who this might be right for
Chronic Myelomonocytic Leukemiade Novo Myelodysplastic SyndromeMyelodysplastic Syndrome+1 more
Fred Hutchinson Cancer Center 50
Testing effectiveness (Phase 2)Study completedNCT02452346
What this trial is testing

Study of Clinical Efficacy and Safety of Tosedostat in MDS

Who this might be right for
Myelodysplastic Syndrome
Weill Medical College of Cornell University 12
Testing effectiveness (Phase 2)Study completedNCT02447666
What this trial is testing

Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)

Who this might be right for
Myelodysplastic SyndromeLeukemia, Myelomonocytic, Juvenile
Celgene 28
Testing effectiveness (Phase 2)Looking for participantsNCT07304011
What this trial is testing

Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent

Who this might be right for
Acute Myeloid Leukemia
University of California, Davis 28
Testing effectiveness (Phase 2)Study completedNCT01993641
What this trial is testing

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA

Who this might be right for
Myelodysplastic SyndromeMDS
Helsinn Healthcare SA 45
Testing effectiveness (Phase 2)Temporarily pausedNCT04278768
What this trial is testing

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Who this might be right for
Acute Myelogenous LeukemiaMyelodysplastic Syndrome
Curis, Inc. 366
Early research (Phase 1)Study completedNCT02429466
What this trial is testing

Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors

Who this might be right for
Germ Cell TumorTestis CancerTesticular Cancer
Nasser Hanna 14
Testing effectiveness (Phase 2)UnknownNCT04541277
What this trial is testing

Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy

Who this might be right for
Acute Myeloid Leukemia, in Relapsed or RefractoryAcute Myeloid Leukemia, Elderly, UnfitAcute Myeloid Leukemia With Positive Minimal Residual Disease
Chinese PLA General Hospital 55
Testing effectiveness (Phase 2)Ended earlyNCT04691141
What this trial is testing

Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome
Shanghai Antengene Corporation Limited 15
Testing effectiveness (Phase 2)Study completedNCT00748553
What this trial is testing

A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer

Who this might be right for
Advanced or Metastatic Solid TumorsAdvanced or Metastatic Breast Cancer
University of Utah 30
Testing effectiveness (Phase 2)Looking for participantsNCT06511882
What this trial is testing

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

Who this might be right for
Acute Myeloid Leukemia
H. Lee Moffitt Cancer Center and Research Institute 37
Testing effectiveness (Phase 2)WithdrawnNCT03709550
What this trial is testing

Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma in the Soft Tissue+6 more
Roswell Park Cancer Institute
Testing effectiveness (Phase 2)Study completedNCT02811497
What this trial is testing

Study of Azacitidine and Durvalumab in Advanced Solid Tumors

Who this might be right for
Microsatellite Stable Colorectal CarcinomaPlatinum Resistant Epithelial Ovarian Cancer Type IIEstrogen Receptor Positive and HER2 Negative Breast Cancer
University Health Network, Toronto 28
Not applicableUnknownNCT04454580
What this trial is testing

Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

Who this might be right for
Acute Myeloid Leukemia, AdultHypomethylating AgentsVenetoclax
Ospedale Maggiore Di Trieste 15
Early research (Phase 1)Active Not RecruitingNCT03613532
What this trial is testing

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Chronic Myelomonocytic Leukemia (CMML)+2 more
Jacqueline Garcia, MD 102
Testing effectiveness (Phase 2)Active Not RecruitingNCT06379360
What this trial is testing

Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

Who this might be right for
Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University 60
Not applicableStudy completedNCT02378701
What this trial is testing

Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 102
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07060001
What this trial is testing

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukaemia (AML)
The Methodist Hospital Research Institute 112
Next Page